Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer

BMC Cancer

Hanbyoul Cho²  Joon-Yong Chung²  Kwon-Ho Song¹  Kyung Hee Noh¹  Bo Wook Kim²  Eun Joo Chung³  Kris Ylaya²  Jin Hee Kim¹  Tae Woo Kim¹  Stephen M Hewitt²  Jae-Hoon Kim⁴ 

[1] Department of Biochemistry, Korea University College of Medicine, Seoul, Korea

[2] Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA

[3] Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA

[4] Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, 146-92 Dogok-Dong, Gangnam-Gu, Seoul 135-720, South Korea

关键词: Immunohistochemistry;    Tissue microarray;    Cervical cancer;    Prognosis;    pERK1/2;    API5;   

Others  :  1125285
DOI  :  10.1186/1471-2407-14-545

 received in 2014-03-13, accepted in 2014-07-17,  发布年份 2014

【 摘 要 】

Background

The apoptosis inhibitor-5 (API5), anti-apoptosis protein, is considered a key molecule in the tumor progression and malignant phenotype of tumor cells. Here, we investigated API5 expression in cervical cancer, its clinical significance, and its relationship with phosphorylated extracellular signal-regulated kinase 1 and 2 (pERK1/2) in development and progression of cervical cancer.

Methods

API5 effects on cell growth were assessed in cervical cancer cell lines. API5 and pERK1/2 immunohistochemical staining were performed on a cervical cancer tissue microarray consisting of 173 primary cervical cancers, 306 cervical intraepithelial neoplasias (CINs), and 429 matched normal tissues.

Results

API5 overexpression promoted cell proliferation and colony formation in CaSki cells, whereas API5 knockdown inhibited the both properties in HeLa cells. Immunohistochemical staining showed that API5 expression increased during the normal to tumor transition of cervical carcinoma (P < 0.001), and this increased expression was significantly associated with tumor stage (P = 0.004), tumor grade (P < 0.001), and chemo-radiation response (P = 0.004). API5 expression levels were positively associated with pERK1/2 in cervical cancer (P < 0.001) and high grade CIN (P = 0.031). In multivariate analysis, API5+ (P = 0.039) and combined API5+/pERK1/2+ (P = 0.032) were independent prognostic factors for overall survival.

Conclusions

API5 expression is associated with pERK1/2 in a subset of cervical cancer patients and its expression predicts poor overall survival, supporting that API5 may be a promising novel target for therapeutic interventions.

【 授权许可】

   
2014 Cho et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [2]Vale CTJ, Stewart LA, Brady M, Dinshaw K, Jakobsen A, Parmar MK, Thomas G, Trimble T, Alberts DS, Chen H, Cikaric S, Eifel PJ, Garipagaoglu M, Keys H, Kantardzic N, Lal P, Lanciano R, Leborgne F, Lorvidhaya V, Onishi H, Pearcey RG, Pras E, Roberts K, Rose PG, Thomas G, Whitney CW: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008, 26(35):5802-5812.
• [3]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
• [4]Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
• [5]Kehmeier E, Ruhl H, Voland B, Stoppler MC, Androphy E, Stoppler H: Cellular steady-state levels of “high risk” but not “low risk” human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities. Virology 2002, 299(1):72-87.
• [6]Vermeulen K, Van Bockstaele DR, Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005, 84(10):627-639.
• [7]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
• [8]Kolch W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005, 6(11):827-837.
• [9]Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270(5240):1326-1331.
• [10]Tewari M, Yu M, Ross B, Dean C, Giordano A, Rubin R: AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Cancer Res 1997, 57(18):4063-4069.
• [11]Morris EJ, Michaud WA, Ji JY, Moon NS, Rocco JW, Dyson NJ: Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet 2006, 2(11):e196.
• [12]Garcia-Jove Navarro M, Basset C, Arcondeguy T, Touriol C, Perez G, Prats H, Lacazette E: Api5 contributes to E2F1 control of the G1/S cell cycle phase transition. PLoS One 2013, 8(8):e71443.
• [13]Van den Berghe L, Laurell H, Huez I, Zanibellato C, Prats H, Bugler B: FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2. Mol Endocrinol 2000, 14(11):1709-1724.
• [14]Krejci P, Pejchalova K, Rosenbloom BE, Rosenfelt FP, Tran EL, Laurell H, Wilcox WR: The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J Leukoc Biol 2007, 82(6):1363-1364.
• [15]Sasaki H, Moriyama S, Yukiue H, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y: Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer. Lung Cancer 2001, 34(1):53-57.
• [16]Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW: API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res 2014, 74(13):3556-3566.
• [17]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
• [18]Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, Seong SY, Kim TW: Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009, 122(1):58-67.
• [19]Kang TH, Noh KH, Kim JH, Bae HC, Lin KY, Monie A, Pai SI, Hung CF, Wu TC, Kim TW: Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res 2010, 70(8):3062-3070.
• [20]Kim JW, Cho HS, Kim JH, Hur SY, Kim TE, Lee JM, Kim IK, Namkoong SE: AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis. Lab Invest 2000, 80(4):587-594.
• [21]Narayanan R, Kim HN, Narayanan NK, Nargi D, Narayanan B: Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels. Int J Oncol 2012, 40(1):13-20.
• [22]Chapman WB, Lorincz AT, Willett GD, Wright VC, Kurman RJ: Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1992, 11(3):221-226.
• [23]Shen MR, Lin AC, Hsu YM, Chang TJ, Tang MJ, Alper SL, Ellory JC, Chou CY: Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem 2004, 279(38):40017-40025.
• [24]Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C: Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2011, 22(10):2166-2178.
• [25]Huang YF, Shen MR, Hsu KF, Cheng YM, Chou CY: Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer 2008, 99(7):1096-1102.
• [26]Branca M, Ciotti M, Santini D, Bonito LD, Benedetto A, Giorgi C, Paba P, Favalli C, Costa S, Agarossi A, Alderisio M, Syrjänen K, HPV-Pathogen ISS Study Group: Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004, 122(6):902-911.
• [27]Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006, 66(7):3903-3911.
• [28]Fang JY, Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005, 6(5):322-327.
• [29]Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26(22):3291-3310.
• [30]Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65(4):663-675.
• [31]Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995, 9(9):726-735.
• [32]Yoon S, Seger R: The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24(1):21-44.
• [33]Rigou P, Piddubnyak V, Faye A, Rain JC, Michel L, Calvo F, Poyet JL: The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation. EMBO J 2009, 28(11):1576-1588.
• [34]Su DM, Zhang Q, Wang X, He P, Zhu YJ, Zhao J, Rennert OM, Su YA: Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol Cancer Ther 2009, 8(5):1292-1304.
• [35]Wang Z, Liu H, Liu B, Ma W, Xue X, Chen J, Zhou Q: Gene expression levels of CSNK1A1 and AAC-11, but not NME1, in tumor tissues as prognostic factors in NSCLC patients. Med Sci Monit 2010, 16(8):CR357-CR364.
• [36]Koci L, Chlebova K, Hyzdalova M, Hofmanova J, Jira M, Kysela P, Kozubik A, Kala Z, Krejci P: Apoptosis inhibitor 5 (API-5; AAC-11; FIF) is upregulated in human carcinomas in vivo. Oncol Lett 2012, 3(4):913-916.